Myeloma Patient Registered to Run His 90th Marathon with Cancer

Don Wright didn't let his 2003 myeloma diagnosis stop him in tracks. This weekend, Don is registered to run his 90th marathon with myeloma in Washington, D.C. The 74-year old says he's managed his cancer for seven of the last twelve years with oral cancer therapies, but knows “multiple myeloma cannot be cured, so I am counting on continuing progress, research and access to the latest treatments to provide the next remission and the remission after that.”
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Conclusiones: El tratamiento de la OMAM depende del estadio de la enfermedad; la mandibulectomía es un tratamiento efectivo en el estadio 3 y la secuestrectomía en el estadio 2; el estadio 1 suele controlarse con tratamiento conservador.ABSTRACT Introduction: Bisphosphonates are a family of drugs used to inhibit bone resorption. One of their secondary effects is osteonecrosis of the jaws (ONJ). In 2010, scientists began to publish cases of osteonecrosis of the jaws associated with a new drug, denosumab. In 2014 it was recommended to change the name of ONJ to medication-related osteonecrosis of the jaws (MONJ)...
Source: Revista Espanola de Cirugia Oral y Maxilofacial - Category: ENT & OMF Source Type: research
Conclusion Prescription drug coverage is associated with decreased use of classic cytotoxic chemotherapy and better survival among Medicare beneficiaries with myeloma, which suggests improved access to all existing treatment options. As oral targeted agents increasingly replace parenteral chemotherapy in oncology, adjustments in coverage policy are needed to ensure access to optimal treatment. PMID: 30113885 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
The objective of this study was to examine the extent to which interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF- α ) are associated with oral health quality of life among patients who underwent HSCT. A. C. Camargo Cancer Center patients were evaluated over 20 months at 4 different time-points: a) at patient admission (M1); b) on the day of infusion of HSC (M2); c) 12 and 20 days after the first day of the conditioning regimen for autologous and allogeneic transplantation, respectively (M3); and d) 30 days after the first day of the conditioning regimen (M4). Mucositis clinical evaluations were performed usi...
Source: Brazilian Oral Research - Category: Dentistry Source Type: research
Publication date: 15 October 2018Source: Biosensors and Bioelectronics, Volume 117Author(s): Shaowei Ding, Suprem R. Das, Benjamin J. Brownlee, Kshama Parate, Taylor M. Davis, Loreen R. Stromberg, Edward K.L. Chan, Joseph Katz, Brian D. Iverson, Jonathan C. ClaussenAbstractVertically aligned carbon nanotube array (VANTA) coatings have recently garnered significant attention due in part to their unique material properties including light absorption, chemical inertness, and electrical conductivity. Herein we report the first use of VANTAs grown via chemical vapor deposition in a 2D interdigitated electrode (IDE) footprint wi...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
CONCLUSIONS: Microwave ablation is an effective and safe treatment technique for painful spinal metastases. Further studies may be helpful in determining the role of microwave ablation in locoregional control of metastases.
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: SPINE Source Type: research
Publication date: 15 October 2018Source: Biosensors and Bioelectronics, Volume 117Author(s): Shaowei Ding, Suprem R. Das, Benjamin J. Brownlee, Kshama Parate, Taylor M. Davis, Loreen R. Stromberg, Edward K.L. Chan, Joseph Katz, Brian D. Iverson, Jonathan C. ClaussenAbstractVertically aligned carbon nanotube array (VANTA) coatings have recently garnered significant attention due in part to their unique material properties including light absorption, chemical inertness, and electrical conductivity. Herein we report the first use of VANTAs grown via chemical vapor deposition in a 2D interdigitated electrode (IDE) footprint wi...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) worsens oral health-related quality of life. Most BRONJ occurs in multiple myeloma or metastatic breast cancer patients treated with bisphosphonate/chemotherapeutic combination therapies. Cyclophosphamide (CY), an alkylating chemotherapeutic drug, is used to treat multiple myeloma, although its use has been recently reduced. The aim of this study was to clarify the effects of CY dose on tooth extraction socket healing when CY is used with or without bisphosphonate in mice.
Source: Bone - Category: Orthopaedics Authors: Tags: Full Length Article Source Type: research
Pomalidomide promotes chemosensitization of pancreatic cancer by inhibition of NF-κB. Oncotarget. 2018 Mar 16;9(20):15292-15301 Authors: Shirai Y, Saito N, Uwagawa T, Shiba H, Horiuchi T, Iwase R, Haruki K, Ohashi T, Yanaga K Abstract Introduction: Nuclear factor κB (NF-κB) plays an important role in cancer progression and causes therapeutic resistance to chemotherapy. Pomalidomide, a third-generation immunomodulating drug derived from thalidomide, has been approved for uncontrolled multiple myeloma. We hypothesized that pomalidomide may inhibit the anticancer agent-induced NF-κ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
We reported a case of MCD who received chemotherapy by ECHOP with unsatisfactory outcome and then oral administration with thalidomide combined with prednisone without disease progression after therapy. After 3 years, his MCD turned into multiple myeloma (MM) and accompanied by obvious response to combination of thalidomide with prednisone. Nowadays, there is no standard of therapy yet established for MCD. We successfully treated one such patient and found thalidomide based therapy may have a significant effect on MCD. We also proposed further researches with therapeutic potential about thalidomide for MCD. PMID:...
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
This study carried out the initial validation of documents to standardize the pharmaceutical counseling for patients treated for myeloma so that it can be reproduced from one patient to another regardless of the pharmacist, by standardizing the information issued. This study needs to be completed by a final validation in myeloma patients, free from oral anticancer therapies. PMID: 29573809 [PubMed - as supplied by publisher]
Source: Bulletin du Cancer - Category: Cancer & Oncology Authors: Tags: Bull Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology | Myeloma | Oral Cancer